Metz, Martin; Staubach, Petra; Bauer, Andrea et al.
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of Fc epsilon RI-positive cells in the skinTHERANOSTICS. Bd. 7. H. 5. 2017 S. 1266-1276
Mueller, J.; Bauer, K. N.; Prozeller, D. et al.
Coating nanoparticles with tunable surfactants facilitates control over the protein coronaBIOMATERIALS. Bd. 115. 2017 S. 1-8
Mitzel-Rink, H.; Schepler, H.; Weid, F. et al.
Combination Therapy from Electrochemotherapy and topical Immunotherapy in a Patient with locoregional Melanoma MetastasesJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 35-36
Heller, Philipp; Hobernik, Dominika; Laechelt, Ulrich et al.
Combining reactive triblock copolymers with functional cross-linkers: A versatile pathway to disulfide stabilized-polyplex libraries and their application as pDNA vaccinesJOURNAL OF CONTROLLED RELEASE. Bd. 258. 2017 S. 146-160
Wilden, S.; Schnurre, D.; Grabbe, S. et al.
Comparative Examination Methods in Aftercare of a Patient with malignant MelanomaJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 58-58
Twelkmeyer, T.; Schermann, A. I.; Lin, H. et al.
Contribution of phagocyte depletion and F4/80-and CD11b-deficiency to disease outcome in cutaneous leishmaniasisEXPERIMENTAL DERMATOLOGY. Bd. 26. H. 3. 2017 S. E75-E75
Lang, B.; Schleider, K.; Becker, D. et al.
Correlation of Medication Intake and the Occurrence of cutaneous Squamous Cell CarcinomasJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 39-40
Mailaender, V; MItzel-Rink, H.; Schach, A. et al.
Cutaneous follicular lymphoma: a case of untypical presentation and early relapse in situ after radiotherapyJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 76-76
Schopf, Rudolf
Cyclosporine treatment for psoriasis followed by fathering of a healthy child in a previously infertile maleJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. Bd. 76. H. 6. 2017 S. AB71-AB71
Kaina, B.; Roos, W.; Quiros, S. et al.
Cytotoxicity through BRaf inhibition by vemurafenib in combination with temozolomide or fotemustine in melanoma cellsJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 53-53